- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04339426
Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection
February 16, 2022 updated by: HonorHealth Research Institute
Open-Label, Non-Randomized Study to Evaluate Anti-Malarial/Anti-Infective Combination Therapies in Patients With Confirmed COVID-19 Infection
This study will evaluate anti-malarial/anti-infective single-agent and in combination for patients with confirmed COVID-19 infection.
The first combination to be evaluated is atovaquone and azithromycin.
Study Overview
Detailed Description
This is an open-label, non-randomized study to evaluate anti-malarial/anti-infective single-agents and combination therapies for patients with confirmed COVID-19 infection requiring therapy as determined by risk factors for complication (age, comorbid illness) or the presence of respiratory compromise.
The first combination to be evaluated is atovaquone/azithromycin.
Other combinations may be added to the study at future amendments as information of potential benefit arises.
The first part of the study will enroll 25 evaluable male and female patients 18 years of age or older with confirmed COVID-19 infection.
Study Type
Interventional
Enrollment (Actual)
3
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85258
- HonorHealth
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 95 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and Female patients age 18 years or older
- COVID-19 confirmed positive test results
- High risk for complications including with Medium (5-6) or High (More than or equal to 7) NEWS score
- Hematology criteria: ANC >500 cells/mcl, HGB >9 g/dl, Platelet count >75,000/mcl
- Metabolic criteria: Serum creatinine <2.0 mg/dl or calculated creatinine clearance (using Cockcroft-Gault) >30 ml/min, AST/ALT <5x ULN AND Total Bilirubin WNL (for patients with Gilbert's disease, direct bilirubin <ULN)
Exclusion Criteria:
- COVID-19 negative test result
- Inability to adhere to study protocol requirements
- Inability to provide informed consent
- Other acute or chronic medical or psychiatric condition that in the judgment of the investigator would make the participant inappropriate to take part in the study
- Pregnant and breastfeeding individuals
- QTc interval greater than 470 msecs at baseline
- History of hypersensitivity to atovaquone and/or azithromycin.
- History of known intolerance to atovaquone and/or azithromycin
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Atovaquone/Azithromycin
Atovaquone 750 mg PO Q12H for up to 10 days Azithromycin 500 mg PO Day 1 followed by 250 mg PO daily for up to 10 days (Days 2-10)
|
Atovaquone 750 mg PO Q12H for up to 10 Days Azithromycin 500 mg PO Daily 1 followed by 250 mg PO Daily for up to 10 days (days 2-10)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Virology Cure Rate
Time Frame: 10 days
|
COVID-19 serology testing
|
10 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of GI adverse events
Time Frame: 47 days
|
Measure incidence of diarrhea, vomiting, nausea and constipation
|
47 days
|
Cardiac Toxicity
Time Frame: 10 days
|
12-Lead ECG daily if QTc >500 msec
|
10 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in WBC w Diff, B cells, T cells, NK cells
Time Frame: 10 days
|
Measure blood counts
|
10 days
|
Changes in cytokine levels, IL-1, IL-6, IL-12, IL-18, TNF-a
Time Frame: 10 days
|
Measure changes in plasma cytokines throughout course of infection
|
10 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Michael Gordon, MD, HonorHealth Research Institute
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 20, 2020
Primary Completion (Actual)
February 11, 2022
Study Completion (Actual)
February 11, 2022
Study Registration Dates
First Submitted
April 7, 2020
First Submitted That Met QC Criteria
April 7, 2020
First Posted (Actual)
April 9, 2020
Study Record Updates
Last Update Posted (Actual)
March 4, 2022
Last Update Submitted That Met QC Criteria
February 16, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- COVID-19
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Anti-Bacterial Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Atovaquone
- Azithromycin
Other Study ID Numbers
- HRI-COVID-19-Anti-Malarial-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on Atovaquone/Azithromycin
-
PfizerCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedPlasmodium Falciparum InfectionMalawi
-
U.S. Army Medical Research and Development CommandWithdrawn
-
Modus Therapeutics ABUniversity of OxfordTerminatedMalaria, FalciparumThailand
-
Radboud University Medical CenterCompletedHIV Infections | MalariaNetherlands
-
National Institutes of Health Clinical Center (CC)CompletedHIV | Toxoplasmosis | PCPUnited States
-
Armed Forces Research Institute of Medical Sciences...National Centre for Parasitology, Entomology and Malaria Control, Cambodia; Naval Medical Research Center, Asia (NMRC-A)Active, not recruiting
-
Assistance Publique - Hôpitaux de ParisCompleted
-
GlaxoSmithKlineCompleted
-
Medicines for Malaria VentureRichmond Pharmacology LimitedCompleted